	US 12,112,839 B2
	Data based cancer research and treatment systems and methods
Christopher Shane Colley, Chicago, IL (US); Isaiah Simpson, Chicago, IL (US); Brian Reuter, Chicago, IL (US); Robert Tell, Chicago, IL (US); Hailey Lefkofsky, Chicago, IL (US); Hunter Lane, Chicago, IL (US); Kevin White, Chicago, IL (US); Nike Beaubier, Chicago, IL (US); Stephen Bush, Chicago, IL (US); Aly Khan, Chicago, IL (US); Denise Lau, Chicago, IL (US); Kaanan Shah, Chicago, IL (US); and Eric Lefkofsky, Chicago, IL (US)
Assigned to Tempus AI, Inc., Chicago, IL (US)
Filed by Tempus AI, Inc., Chicago, IL (US)
Filed on Mar. 22, 2023, as Appl. No. 18/188,443.
Application 18/188,443 is a continuation of application No. 16/657,804, filed on Oct. 18, 2019, granted, now 11,705,226.
Claims priority of provisional application 62/902,950, filed on Sep. 19, 2019.
Prior Publication US 2023/0223121 A1, Jul. 13, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G16H 10/60 (2018.01); G16B 30/00 (2019.01); G16B 40/20 (2019.01); G16H 15/00 (2018.01); G16H 20/10 (2018.01); G16H 20/40 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01); G16H 50/70 (2018.01)

CPC G16H 10/60 (2018.01) [G16B 30/00 (2019.02); G16B 40/20 (2019.02); G16H 15/00 (2018.01); G16H 20/10 (2018.01); G16H 20/40 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); G16H 50/50 (2018.01); G16H 50/70 (2018.01)]

20 Claims

1. A method for conducting genomic sequencing, the method comprising the steps of:

storing a set of user application programs wherein each of the programs requires an application specific subset of data to perform application processes and generates a respective genomic variant characterization; and

for each of a plurality of subjects that have cancerous cells and that receive cancer treatment:

a. obtaining clinical records data in original forms where the clinical records data includes cancer state information, treatment types and treatment efficacy information;

b. for each subject, using a next generation genomic sequencer to generate genomic sequencing data for the subject's cancerous cells and normal cells;

c. shaping at least a subset of the genomic sequencing data to generate system structured data;

d. storing the system structured data in a first database; and

e. for each user application program;

i. selecting the application specific subset of data from the first database;

ii. storing the application specific subset of data in a structure optimized for application program interfacing in a second database; and

iii. receiving the respective genomic variant characterization from the user application program for each subject of the respective plurality of subjects; and

iv. storing the respective genomic variant characterization received from the user application program for each subject of the respective plurality of subjects in a third database.